

Reumatología Clínica

Elsevier Editorial System(tm) for

Manuscript Draft

Manuscript Number: REUMATOLCLIN-D-18-00178

Title: Atlas of Axial Spondyloarthritis in Spain 2017: Study Design and Population

Article Type: Artículo especial / Special article

Corresponding Author: Dr. Marco Garrido-Cumbrera, Ph.D.

Corresponding Author's Institution: Universidad de Sevilla

First Author: Marco Garrido-Cumbrera, Ph.D.

Order of Authors: Marco Garrido-Cumbrera, Ph.D.; Victoria Navarro-Compán, Dr.; Pedro Zarco Montejo, Dr.; Eduardo Collantes-Estévez, Dr.; David Galvez-Ruiz, Ph.D.; Olta Brace, Ph.D.; Jorge Chacon-García; Carles Blanch Mur, Ph.D.; Angels Costa Ferrer, angels.costa@novartis.com; Alvaro Hidalgo Vega, Ph.D.; Pedro Plazuelo Ramos; Jordi Gratacós Masmitja

Manuscript Region of Origin: SPAIN

Opposed Reviewers:

Ética de la publicación

1. ¿Su trabajo ha comportado experimentación en animales?:

No

2. ¿En su trabajo intervienen pacientes o sujetos humanos?:

No

3. ¿Su trabajo incluye un ensayo clínico?:

No

4. ¿Todos los datos mostrados en las figuras y tablas incluidas en el manuscrito se recogen en el apartado de resultados y las conclusiones?:

Sí

Atlas of Axial Spondyloarthritis in Spain 2017: Study Design and Population

M. Garrido-Cumbrera. Health & Territory Research, Universidad de Sevilla, Seville, Spain / Spanish Coordinator of Associations of Spondylarthritis (CEADE), Madrid, Spain

V. Navarro-Compán. Department of Rheumatology. University Hospital La Paz, IdiPaz. Madrid, Spain

P. Zarco. Department of Rheumatology, Foundation Hospital of Alcorcón, Madrid, Spain

E. Collantes-Estévez. Department of Rheumatology. Reina Sofia University Hospital. Maimonides Biomedical Research Institute of Cordoba (IMIBIC). University of Cordoba, Cordoba, Spain

D. Gálvez-Ruiz. Health & Territory Research, Universidad de Sevilla, Seville, Spain

O. Braçe. Health & Territory Research, Universidad de Sevilla, Seville, Spain

J. Chacón García. Health & Territory Research, Universidad de Sevilla, Seville, Spain

C. Blanch Mur. Novartis, Barcelona, Spain

A. Costa Ferrer. Novartis, Barcelona, Spain

A. Hidalgo Vega. Universidad de Castilla-La Mancha, Toledo, Spain

P. Plazuelo Ramos. Spanish Coordinator of Associations of Spondylarthritis (CEADE), Madrid, Spain

J. Gratacós Masmitja. Department of Rheumatology, Hospital Universitari Parc Taulí, Sabadell, I3PT. UAB. Spain

Correspondence to:

Prof Marco Garrido-Cumbrera, PhD, Health & Territory Research (HTR). Centro de Investigación, Tecnología e Innovación Manuel Losada Villsante (CITIUS). Universidad de Sevilla. C/ Doctor Rafael Martínez Domínguez, s/n. Seville 41013, Spain. E-mail: mcumbrera@us.es

Atlas of Axial Spondyloarthritis in Spain 2017: Study Design and Population

Objective. Atlas of Axial Spondyloarthritis in Spain 2017 aims to better understand the reality of the patients suffering from this disease from an integrated approach.

Methods. The Atlas 2017 based its results on an extensive cross-sectional patient survey conducted in Spain (2016), validated by a multidisciplinary group of experts on spondyloarthritis.

Results. Data from 680 patients with axSpA were obtained, most of them suffered from AS, were HLA-B27 positive, older than 45 years, and live as part of a couple. A large percentage had university studies, were disabled and members of a patient association. Patients reported a diagnostic delay of 8.5 years, high disease activity (BASDAI 5.5 ± 2.2), moderate-important stiffness (61.0%), medium-high functional limitation (74.9%), and psychological distress (GHQ 5.7 ± 4.5). A total of 54.7% reported taking NSAIDs, 28.4% DMARDs, 36.3% biological therapy and 32.2% were not receiving pharmacological treatment.

Conclusions. The Atlas survey data reveals still a long diagnostic delay, high disease activity, psychological distress, while an important proportion could be undertreated.

Key Words: axial spondyloarthritis; burden of disease; healthcare management; patient perspective.

Atlas de Espondiloartritis Axial en España 2017: Diseño del Estudio y Descripción de la Muestra

Objetivo. El Atlas de Espondiloartritis Axial en España 2017 tiene como objetivo comprender mejor la realidad de los pacientes que padecen esta enfermedad desde un enfoque integrado.

Métodos. Atlas 2017 basó sus resultados en una amplia encuesta transversal de pacientes realizada en España (2016), validada por un grupo interdisciplinar de expertos en espondiloartritis.

Resultados. Se obtuvieron datos de 680 pacientes con EspAax. La mayoría de ellos sufría EA, eran HLA-B27 positivo, mayores de 45 años y vivían en pareja. Un gran porcentaje tenía estudios universitarios, discapacidad reconocida y era miembro de una asociación de pacientes. Los pacientes declararon un retraso diagnóstico de 8,5 años, alta actividad de la enfermedad (BASDAI $5,5 \pm 2,2$), rigidez moderada-importante (61,0%), limitación funcional media-alta (74,9%) y problemas psicológicos (GHQ $5,7 \pm 4,5$). Un total de 54,7% declaró estar tomando AINE, el 28,4% FAME, el 36,3% terapia biológica, mientras que el 32,2% no recibía ningún tipo de tratamiento farmacológico.

Conclusiones. Los datos de la encuesta de Atlas revelan todavía un enorme retraso diagnóstico, alta actividad de la enfermedad, problemas psicológicos, mientras que una proporción importante de pacientes podrían estar infratratados.

Palabras clave: espondiloartritis axial; carga de la enfermedad; gestión de la atención sanitaria; perspectiva del paciente

Introduction

The term Spondyloarthritis (SpA) describes a group of chronic inflammatory diseases that share clinical, pathogenic, genetic, radiological, epidemiological, and therapeutic response characteristics¹. Currently, patients with SpA are commonly classified according to the predominant manifestations in peripheral and axial SpA (axSpA)^{2,3}. At the same time, axSpA includes Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA), which represents a form of axSpA without a substantial radiographic structural damage.

Nowadays, the mean estimated AS prevalence in Europe (from 36 eligible studies) is 23.8 per 10,000⁴. Disease onset occurs commonly before 45 years of age, leads to severe functional disability and loss of work capacity, though generally coinciding with a productive life period⁵. Some studies have shown an unemployment rate of 25% among AS patients; in up to 21% of cases this is attributed to the disease⁶. In this sense, one main challenge of axSpA is the huge diagnostic delay, which prevents initiating the most appropriate treatment during the initial phases. This is largely associated with disease progression, irreversible structural damage, and loss of patient mobility⁷⁻⁹. During the last decade, many advances in the field of axSpA have been achieved. In 2009, the ASAS classification criteria for axSpA were developed, including the implementation of the magnetic resonance imaging of the sacroiliac joints in patients with suspected axSpA^{1,10}. This results in an increased ability to detect inflammation during the first stages of the disease, much longer before structural damage can be detected by other methods, such as x-ray or computed tomography¹¹. In addition, new therapies (biological therapies) have been developed and have shown to be efficacious in patients with axSpA too.

In Spain, data available for both diagnosis and disease outcomes are drawn from studies completed more than a decade ago^{12,13}. Therefore, to date, it is unknown whether or not all the medical advances achieved have had any impact on the course of the disease and quality of life of patients. On the other hand, there is a wealth of information about axSpA from the clinical point of view, in addition to the most appropriate pharmacological treatments. However, few studies have evaluated aspects such as healthcare planning, treatment resources, reasons for diagnostic delay, functional limitations, psychological status, productivity losses, costs associated with disease management, or patient opinion. Thus, it was decided to undertake the Atlas of Axial Spondyloarthritis in Spain 2017 project.

The Atlas 2017 aims to better understand the current reality of people suffering from axSpA from an integrative perspective based on scientific evidence, expert knowledge, and patient opinion. The study objectives were to assess the main barriers and difficulties for diagnosis, health care, pharmacological and non-pharmacological treatments, labour

productivity losses, and the direct health and non-medical costs of the Spanish National Health System derived from the disease.

Methods

Working group

Atlas 2017 is an initiative of the Spanish Coordinator of Patient Associations of Spondylarthritis (CEADE), carried out by the research group Health & Territory Research (HTR) of the University of Seville and the Max Weber Institute, with the collaboration of the Spanish Society of Rheumatology (SER) and sponsored by Novartis Farmacéutica, Spain.

The study included a scientific committee composed of four rheumatologists belonging to the Spanish Group of Spondyloarthritis of the Spanish Society of Rheumatology (GRESSER), two patients with axSpA representing the patient association, two primary care physicians, three health economists, and one health geographer. An advisory committee was also established which consisted of two psychologists, one nurse, one pharmacist, and one physiotherapist. All of the professionals had experience in the clinical care of patients and/or in the development of epidemiological studies. The members of the scientific committee were charged with assessing and validating the study results, as well as making proposals to better understand the current management of axSpA in Spain. In order to do so, the committee met three times over the course of a year. The advisory committee supported the resolution of doubts about specific matters, communicating mainly through the internet and via teleconferences.

Survey

A patient questionnaire was designed for individuals suffering from axSpA based on expert opinion of a panel of rheumatologists and patients with axSpA and a broad literature review to identify relevant aspects related to axSpA in the following areas: diagnosis, treatment, comorbidity, employment, limitations and psychological state from 2000 up until November 2017. Articles were limited to studies in the English or Spanish language. Inclusion criteria were age of 18 years or older (adults), being diagnosed of axSpA, and live in Spain during the survey. The questionnaire, developed over four months (from January to April 2016), was used in a pilot study of a group of 17 axSpA patients belonging to different age groups and with varying educational levels. This sample was personally interviewed in different rounds.

This process allowed for the development of the questionnaire in its final version, which is composed of 116 items and four open-ended qualitative questions that are included in the 16 thematic domains described in Table 1.

Table 1 Variables included within the patient questionnaire of the Atlas 2017

The dissemination of the patient questionnaire for the recruitment of a sufficient representative sample size was made through general and specific press releases to the medical community, emails to SpA patient association members, CEADE website, websites of local SpA patient associations, patients' social networks, and during the I Spanish Annual Meeting of Patients with Spondyloarthritis. A total of 838 patients with axSpA anonymously accessed the online questionnaire between May 1 and August 15, 2016. After the validation and normalisation of the information, the sample consisted of a total of 680 patients who responded to the majority of the questionnaire (completion rate was higher than 75%).

Indices and scales for the assessment of disease effects

In addition to the items included in Table 1, the patients included in the study completed five indices, two of which had been previously validated - the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the General Health Questionnaire (GHQ-12). Three others created specifically for this project were also included: the Spinal Stiffness Index, the Functional Limitation Index, and the Beneficial Physical Activities Index.

BASDAI: Self-reported disease status was measured using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)¹⁴. The BASDAI scale measures disease activity in patients with AS. It can be self-administered and includes six questions pertaining to the following symptoms: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness, and morning stiffness, rated on an analog scale from 0 (no activity) to 10 (maximum activity). This instrument has shown good psychometric properties and applicability to everyday clinical practice¹⁵. In the present study, the Cronbach's alpha score for the BASDAI was 0.879, close to one and above the minimum established levels, which guarantees that this scale is reliable to measurement of the self-reported disease activity.

GHQ-12: developed by Goldberg and Williams in 1988, this questionnaire assesses the severity of psychological distress during the weeks prior to participation, with the objective of detecting psychological morbidity and possible cases of psychiatric disorders^{16,17}. The validated cut-off point on the GHQ scale for the Spanish version of the questionnaire is ≥ 3 , indicating that individuals with a score of ≥ 3 may be experiencing psychological distress¹⁸. The GHQ-12 shows good reliability in the various studies carried out with Cronbach's alphas ranging from 0.82 to 0.86¹⁹. A recent study developed in Spain describes a Cronbach's alpha of 0.76¹⁶. In our study, we obtained a Cronbach's alpha of 0.934 which supports the hypothesis of the scale reliability.

Spinal Stiffness Index: based on the ASAS concept of spinal stiffness which is defined by intensity and duration upon awakening²⁰. Therefore, one of the questionnaire items aimed at assessing the degree of spinal stiffness experienced by patients, distinguishing between the three spinal regions: cervical, thoracic, and lumbar. The index resulted from adding unweighted

degree of rigidity in these three regions on a scale of lesser to greater effect (from 0 to 9): where a value of 0 would imply no stiffness, between 1 and 3 light stiffness, between 4 and 5 moderate stiffness, and between 6 and 9 significant stiffness. In our study we obtained a Cronbach alpha of 0.850, which confirms the reliability of this scale for the assessment of stiffness.

Functional Limitation Index: generated by adding the non-weighted degree of functional limitation registered for 18 different activities of daily living (dressing, grooming, bathing, tying shoelaces, moving around the home, stairs, getting to/out of bed, toilet, shopping, preparing meals, eating, cleaning, walking, using public transportation, going to the doctor, driving, physical exercise, sexual relations), using a score of 0 to 3 (0 no limitation, 1 low limitation, 2 medium limitation, and 3 high limitation), with a total result between 0 and 54. Thus, a global functional limitation value between 0 and 18 would imply low limitation, between 18 and 36 medium limitation, and between 36 and 54 high limitation. The Cronbach alpha value obtained for this scale is 0.964, guaranteeing its reliability as an instrument for assessing limitation.

Beneficial Physical Activities Index: not all physical activities are beneficial for patients with axSpA and, therefore, it was necessary to identify the appropriate activities²¹. In particular, physical activities that promote good posture are recommended, as well as extending and rotating the trunk²². To evaluate the performance of beneficial physical activities, a dichotomous indicator was established including six beneficial physical activities classified (Pilates, meditation, yoga, swimming, aquaerobics, and aquagym) according to expert opinion and the results from the systematic literature review²³⁻²⁵.

The calculation of direct health and non-medical costs was made using the social perspective by multiplying the resources used by each patient with AS, for the unit price of each resource, in the year prior to answer the questionnaire. This data was self-reported by patients. Direct health costs include the AS-related cost of medical visits, medical tests, emergencies, hospital admissions, and medication (pharmacological and administration costs). Direct non-medical costs include alternative treatments for AS in the preceding 12 months (e.g. acupuncture and homeopathy) and expenditures on rehabilitation therapies or physical exercise, indicated directly by patients in monetary value (no including household and car adaptations, nor the out-of-pocket expenses incurred in transportation).

Productivity losses refer to reduced labour productivity related to AS (ability to meet a schedule, reduced working hours, temporary and permanent sick leave, or early retirement). Following the Human Capital approach, a cost has been allocated to working days lost or lost wages. For this, the average wage was assigned according to gender and occupation level; in the case of workers and temporary sick leave, and the average wage according to gender, and

average hours worked per year for the other situations that imply productivity loss. The wage data was extracted from the National Statistics Institute of Spain (INE)²⁶.

Results

A total of 838 patients with axSpA accessed the questionnaire. After the validation and homogeneity process, the survey database was comprised of a total of 680 patients, distributed homogeneously by gender through the 17 Spanish Autonomous Communities.

The sociodemographic characteristics of the included patients are detailed in Table 2. Gender distribution was homogeneous across the sample. The majority of patients were married, within the range of working ages, and with a significant percentage having some degree of recognised disability. On the other hand, although an important part of the survey dissemination was carried out through SpA patient associations, less than half of respondents were members of one of these patient associations.

Table 2 Sociodemographic characteristics of the 680 survey respondents included in the Atlas

Table 3 shows the clinical self-reported characteristics of patients. In addition to the data shown in this table, it is noteworthy that 61% of patients reported moderate to severe stiffness and 74.9% had a medium-high degree of limitation. On the other hand, 76.7% of the patients presented a BASDAI above the cut-off point for active disease (≥ 4). Similarly, the GHQ-12 mean score exceeded the cut-off point to define psychological distress (≥ 3) with 65.4% of the patient above this point¹⁸, with the main comorbidities self-reported being anxiety, sleep disorder, uveitis, depression and overweight/obesity. Most patients were taking NSAIDs, followed by biological therapy, and DMARDs. However, a significant percentage of patients reported that they were not currently receiving any pharmacological treatment despite the 2016 update of the ASAS-EULAR management recommendations for axSpA²⁷.

Table 3 Clinical self-reported characteristics of patients included in the Atlas 2017, according to patient responses

Atlas 2017 also assesses the economic burden of AS in Spain. The social perspective was used and the estimated average cost per patient per year was €11,462.3 (including direct health care costs, direct non-medical costs and productivity losses). Of this total, more than half

are related to direct health costs, followed by costs associated with labour productivity loss and, finally, direct non-medical costs (Table 5).

Table 4 Average cost per year of AS patients in Spain, and cost distribution in 2015.

Discussion

Atlas 2017 is the most ambitious project promoted from CEADE to date and aims to respond to a shortage of information on axSpA in Spain, including the patient's perspective. The data collected provide a comprehensive and current vision of axSpA in Spain and the implications for patients coping with this chronic condition. The main tool of the Atlas has been the anonymous online survey carried out on a wide sample of patients distributed throughout the country, promoted, and disseminated by the CEADE patient associations. However, this was not a limitation since only 44.3% of respondents were members of patient associations.

Among the most relevant data, we should highlight a diagnosis delay of 8.5 years and the large burden associated with the disease in terms of disability. This describes a worrisome situation and highlights the difficulties that still persist today regarding early diagnosis, which could largely prevent its evolution. In addition, less than 50% of respondents were working at the time of the survey, which is of concern considering that the average age was around 45 years. On the other hand, the mean 5.5% BASDAI reported by patients indicates that, for most, the disease is not controlled. Finally, this study also demonstrates the great psychological impact of this disease, since the GHQ-12 showed a high average score (value 5.7). Using this data, a document was created (English and Spanish versions are available at www.espondiloartritisaxial.org/atlas) that deepens the knowledge of axSpA in Spain and provides new evidence aimed at improving patient care and quality of life.

One of the main contributions of the Atlas 2017 has been the incorporation of the patient's perspective. Unlike other reports or research carried out on axSpA, it not only seeks to capture the burden of disease from a medical and health perspective, but also to reflect the patient's overall experience in terms of the physical, social, emotional, labour and economic limitations, among others. This study outlines the importance of a strong partnership developed between researchers (academic institutions), scientific societies of rheumatology, healthcare professionals and patients with rheumatic diseases.

In the future, the database derived from the Atlas 2017 survey will allow analysts to answer key research questions, such as: what are the reasons for the diagnostic delay?; what are the key risk factors for structural damage?; how does the disease severity affect psychological distress?; what is the relationship between unhealthy habits and disease activity?; or the possible benefits of belonging to a patient association.

However, the Atlas 2017 project does have a number of limitations. In the first place, having collected the data through a patient survey online, this could bias the study results since it is possible that patients with higher disease severity tend to respond more frequently to surveys. Being self-reported patient information, there may be some difficulty ensuring proper SpA diagnosis and accurately establishing the type of axSpA experienced^{12,13}. On the other hand, it should be noted that the survey did not collect direct non-medical costs related to the transportation of patients to attend consultations, tests, emergencies, and other health services. Likewise, it did not include information about professional and informal care received by patients, nor about adaptations made to housing as a result of physical limitations. Previous studies have shown that patients with advanced AS can incur significant out-of-pocket costs to cover informal care and accommodation²⁸. Therefore, it was necessary to estimate the cost related to informal care and housing adaptations, taking data from the literature.

The Atlas 2017 has achieved great impact at national level, being published by the Institute Max Weber²⁹. Likewise, a multitude of informative support content has been generated, including the specific web of the Atlas 2017 (www.espondiloartritisaxial.org/atlas/), infographics, and a documentary aimed at enhancing scientific and social understanding. Proof can be seen in the high number of downloads relating to this document to date. On the other hand, the Atlas data are being presented and discussed with the regional health authorities of Spain (Autonomous Communities) to put the axSpA in the health agendas in order to plan and implement solutions at National Health Service level to improve patient's health.

The Atlas 2017 has been considered a benchmark study. As a result, its methodology is being implemented in 12 other European countries (Belgium, Germany, France, United Kingdom, Italy, Norway, the Netherlands, Slovenia, Switzerland, Sweden, Russia, and Austria) under a joint project called EMAS (The European Map of Axial Spondyloarthritis). EMAS is promoted by the Ankylosing Spondylitis International Federation (ASIF), CEADE, and the University of Seville. In this way, it is intended to assess the existing inequalities and disparities between countries and establish recommendations aimed at improving patient care in Europe.

Conclusions

The Atlas 2017 aims to better understand the current reality of people suffering from axSpA from an integrative perspective based on scientific evidence, expert knowledge, and patient opinion. The patient survey data shows still a long diagnostic delay, high disease activity, psychological distress, while an important proportion could be undertreated.

Acknowledgements

Funding: We would like to thank all the patients who volunteered participated in the Survey promoted by the Spanish Coordinator of Associations of Spondyloarthritis (CEADE).

This work was supported by Novartis Farmacéutica S.A.

References

1. Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Ann Rheum Dis.* 2009; 68(6):770–6.
2. van Tubergen A. The changing clinical picture and epidemiology of spondyloarthritis. *Nat Rev Rheumatol.* 2015; 11(2):110–118
3. Sepriano A, Rubio R, Ramiro S, Landewé R, van der Heijde D. Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis. *Ann Rheum Dis.* 2017; 76(5):886-890.
4. Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. *Rheumatology.* 2014; 53(4):650–657.
5. Boonen A, van der Heijde D, Landewe R, Rutten M, Spoorenberg A, Schouten H, et al. Work status and productivity costs due to ankylosing spondylitis: comparison among three European countries. *Ann Rheum Dis.* 2002; 61(5):429–37
6. Montacer Kchir M, Mehdi Ghannouchi M, Hamdi W, Azzouz D, Kochbati S, Saadellaoui K, et al. Impact of the ankylosing spondylitis on the professional activity. *Joint Bone Spine.* 2009; 76(4):378–82.
7. Deodhar A, Mittal M, Reilly P, Bao Y, Manthena S, Anderson J, et al. Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. *Clin Rheumatol.* 2016; 35(7):1769-76.
8. Nakashima Y, Ohishi M, Okazaki K, Fukushi J-I, Oyamada A, Hara D, et al. Delayed diagnosis of ankylosing spondylitis in a Japanese population. *Mod Rheumatol.* 2016; 26(3):421–5.
9. Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. *Curr Opin Rheumatol.* 2000; 12(4):239-47.
10. Akgul O, Ozgocmen S. Classification criteria for spondyloarthropathies. *World J Orthop.* 2011; 2(12):107–15.
11. Leone A, Cassar-Pullicino VN, D'Aprile P, Nasuto M, Guglielmi G. Computed Tomography and MR Imaging in Spondyloarthritis. *Radiol Clin North Am.* 2017; 55(5):1009-1021.

12. Collantes E, Zarco P, Muñoz E, Juanola X, Mulero J, Fernández-Sueiro JL, et al. Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. *Rheumatology*. 2007; 46(8): 1309-15.
13. Rojas-Vargas M, Muñoz-Gomariz E, Escudero A, Font P, Zarco P, Almodovar R, et al. First signs and symptoms of spondyloarthritis - data from an inception cohort with a disease course of two years or less (REGISPONSER-Early). *Rheumatology*. 2009; 48(4): 404-9.
14. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol*. 1994; 21(12):2286-91.
15. Haywood KL, Garratt A, Jordan K, Dziedzic K, Dawes PT. Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. *Rheumatology*. 2002; 41(11):1295-302.
16. Sánchez López MP, Dresch V. The 12-Item General Health Questionnaire (GHQ-12): Reliability, external validity and factor structure in the Spanish population. *Psicothema*. 2008; 20(4):839-43.
17. Goldberg D, Williams P () A user's guide to the General Health Questionnaire. Windsor: NFER-Nelson; 1988.
18. Ballbè M, Martínez-Sánchez JM, Gual A, Martínez C, Fu M, Sureda X, et al. Association of second-hand smoke exposure at home with psychological distress in the Spanish adult population. *Addict Behav*. 2015; 50:84-8.
19. Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O, et al. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. *Psychol Med*. 1997; 27:191-7.
20. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis*. 2006; 65(4):442-52.
21. Feldtkeller E, Lind-Albrecht G, Rudwaleit M. Core set of recommendations for patients with ankylosing spondylitis concerning behaviour and environmental adaptations. *Rheumatol Int*. 2013; 33(9):2343-9.
22. Lubrano E, Helliwell P, Moreno P, Griffiths B, Emery P, Veale D. The assessment of knowledge in ankylosing spondylitis patients by a self-administered questionnaire. *Br J Rheumatol*. 1998; 37(4):437-41.
23. Karapolat H, Eyigor S, Zoghi M, Akkoc Y, Kirazli Y, Keser G. Are swimming or aerobic exercise better than conventional exercise in ankylosing spondylitis patients? A randomized controlled study. *Eur J Phys Rehabil Med*. 2009; 45(4):449-57.
24. Santos H, Brophy S, Calin A. Exercise in ankylosing spondylitis: how much is optimum?. *J Rheumatol*. 1998; 25(11):2156-60.
25. Passalent LA, Soever LJ, O'Shea FD, Inman RD. Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. *J Rheumatol*. 2010; 37(4):835-41.

26. Instituto Nacional de Estadística. [Spanish Statistical Office]. www.ine.es
27. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis*. 2017; 76(6):978-991.26.
28. Kobelt G, Sobocki P, Mulero J, Gratacós J, Pocovi A, Collantes-Estevez E. The Burden of Ankylosing Spondylitis in Spain. *Value Health*. 2008; 11(3):408-15.
29. Atlas of Axial Spondyloarthritis in Spain 2017: Profile of the disease, <https://www.espondiloartritisaxial.org/atlas/>; 2017 [accessed 15 March 2018].

Table 1. Variables included within the patient questionnaire of the Atlas 2017

Domains	Variables
Socio-demographic characteristics	Year of birth, gender, level of education, marital status, income level, municipality of residence, AACC and patients association membership.
Anthropometric measures	Weight and height.
Diagnostic delay	Date of first symptoms, date of diagnosis, and tests performed
Healthcare utilisation	Health insurance, health centre visits, visits to health professionals and medical tests related to axSpA.
Comorbidity	Diseases associated to axSpA.
Psychological health	GHQ-12.
Pharmacological treatment of axSpA	Biological therapy, NSAIDs, and DMARDs.
Employment data	Employment status, occupation and number of working hours per week
Labour productivity losses	Problems related to work (to meet a schedule, reduced workday ...), temporary and permanent retirement, or early retirement and difficulties finding employment due to axSpA.
Disability	Assessment and degree of disability.
Inability to work benefits	Benefits for partial or absolute economic benefits due to temporary and permanent inability to work; permanent injury benefit; contributory and non-contributory retirement benefits, and disability benefit.
Disease activity, functional limitation, and stiffness	BASDAI, functional limitation in daily activities, and spinal stiffness.
Physical activities	Walking, running, gymnastics for maintenance, swimming, hiking, meditation, stretching exercises, biking, gymnastics for muscle-building, yoga, dancing, tennis/padel, pilates, aquaerobics, and aquagym.
Complementary treatment	Self-help groups, homeopathy, and acupuncture.
Unhealthy habits	Smoking and alcohol.
Patient opinion	Fears and hopes related to axSpA.

AACC Autonomous Community
axSpA Axial Spondyloarthritis
GHQ-12 General Health Questionnaire - 12 items
BASDAI Bath Ankylosing Spondylitis Disease Activity Index
NSAIDs Nonsteroidal anti-inflammatory drugs
DMARDs Disease-modifying antirheumatic drugs

Table 2. Sociodemographic characteristics of the 680 survey respondents included in the Atlas

	Mean ± SD n (%)
Average, age (years)	45,7 ± 10.8
Gender, Male	323 (47.5)
Disability officially recognised (≥ 33%)	253 (37.2)
University studies	251 (36.9)
Marital Status, Married/Domestic Relationship	486 (71.5)
Employment Status, Employee (n: 653)	325 (49.8)
Patient Association Member	301 (44.3)
Smokers (n: 585)	220 (37.6)

N = 680 Unless otherwise specified

Table 3. Clinical self-reported characteristics of patients included in the Atlas 2017 according to patient responses

	Mean ± SD n (%)
Diagnostic Ankylosing Spondylitis	578 (85)
Diagnostic delay (years) (n: 550)	8.5 ± 7.7
HLA-B27 positive (n: 507)	391 (77.1)
Index and scales	
BASDAI (0-10) (n: 442)	5.5 ± 2.2
GHQ-12 (0-12) (n: 474)	5.7 ± 4.5
Spinal Stiffness Index (0-9) (n: 494)	4.5 ± 2.7
Functional Limitation Index (0-54) (n: 605)	27.7 ± 13.2
Beneficial Physical Activity Index	297 (43.7)
Treatments	
NSAIDs	372 (54.7)
DMARDs	193 (28.4)
Biological therapy	247 (36.3)
Without Pharmaceutical Treatment	219 (32.2)
Uveitis	122 (17.9)
Main Comorbidities	
Anxiety	135 (19.9)
Sleep disorders	134 (19.7)
Uveitis	122 (17.9)
Depression	100 (14.7)
Overweight/obesity	94 (13.8)

N = 680	Unless otherwise specified
HLA-B27	Human Leukocyte Antigen B27
BASDAI	Bath Ankylosing Spondylitis Disease Activity Index
GHQ-12	General Health Questionnaire - 12 items
NSAIDs	Nonsteroidal anti-inflammatory drugs
DMARDs	Disease-modifying antirheumatic drugs
Uveitis	Current or antecedent
Diagnostic Delay	Difference between time from symptom onset and time from diagnosis
Treatments	Last 12 months

Table 4. Average cost per year of AS patients in Spain, and cost distribution in 2015.

	Cost (€)	% over Total Cost
Direct Health Care Costs	6,999.8	61.1
Direct Non-Medical Costs	611.3	5.3
Work Productivity Loss	3,851.2	33.6
Total Cost	11,462.3	100